Rosemary

Rosemary demonstrates dual anticoagulant-relevant effects. Carnosic acid and carnosol exhibit antiplatelet activity by inhibiting thromboxane A2 synthesis and cytosolic calcium mobilisation (Lee JJ et al. Planta Med 2007). Concurrently, in vitro research shows rosemary may induce CYP1A2, potentially increasing warfarin clearance and reducing anticoagulation. Long-term intake of rosemary and common thyme together inhibited experimental thrombosis without prolonging bleeding time. The net clinical effect on INR is uncertain.

Monitor INR in patients on warfarin who use high-dose rosemary extracts. Advise patients to maintain consistent rosemary use and report any changes in bruising patterns. Culinary use of rosemary is unlikely to be clinically significant. Caution is primarily relevant to standardized extracts or essential oil preparations.

In vitro research demonstrates that rosemary extract induces CYP1A2 enzyme activity, which could theoretically increase the metabolic clearance of CYP1A2-metabolized drugs and reduce their plasma concentrations. Rosmarinic acid and carnosol have been identified as the likely inducing constituents. This interaction has not been confirmed in human clinical pharmacokinetic studies.

Monitor therapeutic response in patients taking narrow therapeutic index CYP1A2 substrates (theophylline for asthma, clozapine for schizophrenia) who are simultaneously taking high-dose rosemary extracts. Watch for reduced drug efficacy. Until human data are available, this remains a low-level theoretical concern.

Rosemary extract has demonstrated direct anticonvulsant activity in animal models through multiple mechanisms: potentiation of GABA-A receptor activity (producing sedation and seizure threshold elevation), inhibition of excitatory glutamate neurotransmission, and antioxidant neuroprotective effects. This may synergistically enhance the antiepileptic efficacy of standard medications. However, additive CNS depression with sedating antiepileptics is also possible.

Caution patients with epilepsy about combining rosemary extracts with antiepileptic drugs without neurologist oversight. While potential for beneficial synergy exists, unpredictable CNS depression is the primary concern. Monitor seizure frequency and sedation levels. Rosemary essential oil should never replace prescribed antiepileptic therapy.

Carnosic acid and rosmarinic acid in rosemary improve glycemic control by inhibiting alpha-glucosidase (slowing carbohydrate absorption), enhancing GLUT4 translocation in adipocytes (improving peripheral glucose uptake), and improving insulin signalling. Studies in diabetic animal models showed reduced elevated fasting blood glucose with rosemary extract. Additive blood glucose lowering is possible at therapeutic extract doses.

Advise diabetic patients using rosemary extracts to monitor blood glucose more frequently. Clinical significance is likely low at culinary doses but higher-dose rosemary standardized extracts could contribute to hypoglycaemia in patients on insulin or sulfonylureas. Educate patients on hypoglycaemia signs.

Rosemary is rich in polyphenolic compounds including rosmarinic acid, carnosic acid, and tannins. These polyphenols chelate non-heme iron in the gastrointestinal tract, forming insoluble iron-polyphenol complexes that markedly reduce iron absorption. This is a physico-chemical interaction occurring in the gut lumen, not a pharmacokinetic enzyme-mediated interaction.

Advise patients to take iron supplements at least 2 hours before or 4 hours after rosemary preparations (especially standardized extracts or teas). Monitor haematological response to iron supplementation if co-administration with rosemary extracts cannot be avoided. Culinary rosemary use with meals is unlikely to significantly impair iron absorption.

Rosemary phytochemicals — carnosic acid, carnosol, and ursolic acid — inhibit P-glycoprotein (Pgp/ABCB1) efflux transporter activity in vitro. This inhibition increases intracellular accumulation of Pgp substrate drugs. For digoxin (narrow TI cardiac glycoside) and immunosuppressants (tacrolimus), elevated plasma levels can produce toxicity. In oncology, rosemary may increase intratumoral chemotherapy concentrations but simultaneously raise systemic drug exposure and adverse effects.

Patients on narrow-TI Pgp substrates (digoxin, tacrolimus, certain chemotherapy agents) should be cautioned about rosemary extract supplements. High-dose rosemary extract is distinct from culinary rosemary. Monitor digoxin levels, tacrolimus trough levels, or clinical parameters when rosemary extracts are used concurrently.

Rosemary has mild diuretic properties attributed to its volatile oil constituents and flavonoid content. Concurrent use with loop diuretics, thiazides, or antihypertensive drugs may produce additive blood pressure-lowering and urine output-increasing effects, potentially causing dehydration or excessive hypotension.

Monitor blood pressure and hydration status in patients taking rosemary supplements alongside antihypertensive or diuretic medications. The risk is low at culinary amounts but increases with supplemental-dose extracts. Advise adequate fluid intake and awareness of dizziness symptoms.

Rosemary diuretic activity reduces renal water and sodium excretion, causing compensatory renal lithium reabsorption in the proximal tubule. This can elevate serum lithium concentrations beyond the narrow therapeutic index. Lithium toxicity manifests as tremor, confusion, ataxia, renal impairment, and cardiac arrhythmias. The same mechanism underlies the well-established thiazide-lithium interaction.

Avoid combining rosemary supplements with lithium therapy. If concurrent use is unavoidable, monitor serum lithium levels closely and watch for early toxicity signs including fine tremor, GI disturbance, and polyuria. Educate patients on symptoms of lithium toxicity.

Rosemary has historically been used as an emmenagogue that stimulates or increases menstrual flow. Rosemary constituents modulate estrogen receptor-mediated pathways in preclinical studies. This may create pharmacodynamic interactions with hormonal contraceptives or HRT by potentially disrupting hormonal cycle regulation or altering the estrogenic environment.

Advise patients on hormonal contraceptives or HRT to avoid high-dose rosemary extracts beyond culinary use. While the risk is considered low, emmenagogue effects are not fully characterized in controlled human studies. Culinary use is considered safe. Report any menstrual irregularities to a healthcare provider.